Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Merck & Company (MRK)

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 181,448,960
  • Shares Outstanding, K 2,531,375
  • Annual Sales, $ 47,994 M
  • Annual Income, $ 7,067 M
  • 60-Month Beta 0.41
  • Price/Sales 3.80
  • Price/Cash Flow 10.45
  • Price/Book 5.86
Trade MRK with:

Options Overview

Details
  • Implied Volatility 20.68%
  • Historical Volatility 12.35%
  • IV Percentile 42%
  • IV Rank 21.35%
  • IV High 39.19% on 02/02/21
  • IV Low 15.65% on 09/03/21
  • Put/Call Vol Ratio 0.25
  • Today's Volume 59,497
  • Volume Avg (30-Day) 30,384
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 538,460
  • Open Int (30-Day) 352,950

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 1.51
  • Number of Estimates 4
  • High Estimate 1.59
  • Low Estimate 1.36
  • Prior Year 1.74
  • Growth Rate Est. (year over year) -13.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.89 +1.11%
on 09/17/21
79.23 -9.53%
on 08/23/21
-7.15 (-9.07%)
since 08/17/21
3-Month
70.89 +1.11%
on 09/17/21
79.23 -9.53%
on 08/23/21
-5.55 (-7.19%)
since 06/17/21
52-Week
70.89 +1.11%
on 09/17/21
86.30 -16.94%
on 09/18/20
-13.96 (-16.30%)
since 09/17/20

Most Recent Stories

More News
Merck's KEYTRUDA(R) (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS greater-than or equal to10)

--Data From Phase 3 KEYNOTE-355 Trial Presented at ESMO Congress 2021

MRK : 71.68 (-0.40%)
Merck's KEYTRUDA(R) (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting

--Results From Phase 3 KEYNOTE-716 Trial Selected for Presentation During Presidential Symposium and Official Press Program at ESMO Congress 2021

MRK : 71.68 (-0.40%)
Merck's KEYTRUDA(R) (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

--Results From Phase 3 KEYNOTE-826 Trial Selected for Official Press Program and Presentation During Presidential Symposium at ESMO Congress 2021 and Simultaneously Published in New England Journal of...

MRK : 71.68 (-0.40%)
Turner Syndrome Market: by Industry Type, Growth, Share, Size, Key Manufacturers, Revenue, Trends, Growth, Geographical Outlook and Forecast to 2028

Research Nester published a report titled ": Global Demand Analysis & Opportunity Outlook 2028"which delivers a detailed overview of the turner syndrome drug market in terms of market segmentation by type,...

PFE : 43.89 (-1.30%)
NOVN : 8.56 (+1.30%)
BHC : 27.27 (-1.02%)
JNJ : 164.75 (-0.28%)
LLY : 230.10 (-0.41%)
ABT : 126.79 (-0.51%)
MRK : 71.68 (-0.40%)
SAN : 3.58 (-3.24%)
GSK.LN : 1,388.200 (-0.49%)
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win

AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.

MRK : 71.68 (-0.40%)
LLY : 230.10 (-0.41%)
ABBV : 107.73 (-0.32%)
TBPH : 7.11 (+3.64%)
AERI : 12.94 (+4.86%)
RGNX : 45.04 (+0.92%)
Merck Receives Positive EU CHMP Opinion for KEYTRUDA(R) (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS greater-than or equal to10)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval...

MRK : 71.68 (-0.40%)
NetworkNewsAudio Lexaria Bioscience Corp. (NASDAQ: LEXX) Leading Out in Innovation of Hypertension Treatment

(MENAFN - Investor Brand Network) Hypertension, or high blood pressure, is rampant in America. An estimated 45% of adults in the United States, or 108 million people, have hypertension, yet only about...

LEXX : 6.32 (+2.93%)
PFE : 43.89 (-1.30%)
MRK : 71.68 (-0.40%)
AZN : 55.56 (-1.84%)
MRNA : 430.05 (-2.41%)
Top Research Reports for NVIDIA, Johnson & Johnson & Toyota

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Johnson & Johnson (JNJ), and Toyota Motor Corporation (TM).

NKE : 156.42 (-0.75%)
TM : 180.95 (-0.54%)
JNJ : 164.75 (-0.28%)
MRK : 71.68 (-0.40%)
MMM : 181.49 (-0.64%)
NVDA : 219.00 (-1.54%)
HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers

HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.

GSK : 38.93 (-0.46%)
MRK : 71.68 (-0.40%)
HOOK : 6.74 (+3.06%)
IOVA : 25.47 (+8.15%)
Lymphoproliferative Disorder Treatment Market Emerging Trends, Market Research, And Comprehensive Insights 2028

Research Nester released a report titled "" which delivers detailed overview of the global lymphoproliferative disorder treatment market in terms of market segmentation by route of administration, drug...

ATRA : 16.08 (+1.32%)
NOVN : 8.56 (+1.30%)
MRK : 71.68 (-0.40%)
BMY : 61.31 (+0.13%)
ABBV : 107.73 (-0.32%)
GILD : 71.61 (+0.39%)
AZN.LN : 8,063.001 (-0.96%)
PFE : 43.89 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

3rd Resistance Point 73.27
2nd Resistance Point 72.63
1st Resistance Point 72.16
Last Price 71.68
1st Support Level 71.05
2nd Support Level 70.41
3rd Support Level 69.94

See More

52-Week High 86.30
Fibonacci 61.8% 80.41
Fibonacci 50% 78.60
Fibonacci 38.2% 76.78
Last Price 71.68
52-Week Low 70.89

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar